Brooks Lab.

Which are the latest news on Brooks Lab.?

Why is Brooks Laboratories Ltd falling/rising?

As of 05-Sep, Brooks Laboratories Ltd's stock price is currently at 65.93, reflecting a 2.66% increase after a trend reversal. Despite this short-term recovery, the stock has seen significant declines over the year, with a 17.84% drop year-to-date and a 54.42% decrease over the past year.

As of 05-Sep, Brooks Laboratories Ltd's stock price is rising, currently at 65.93, reflecting an increase of 1.71 or 2.66%. This upward movement follows a trend reversal after two consecutive days of decline. Additionally, the stock has outperformed its sector by 3.13% today, indicating a positive shift in performance relative to its peers.<BR><BR>The stock reached an intraday high of Rs 66.64, marking a 3.77% increase at that point. However, it is important to note that while the stock is currently rising, it has experienced significant declines over longer periods, with a year-to-date drop of 17.84% and a staggering 54.42% decrease over the past year. <BR><BR>Investor participation appears to be declining, as evidenced by a 78.03% drop in delivery volume compared to the five-day average. Despite this, the stock remains liquid enough for trading, suggesting that there is still some interest in the stock. Overall, the recent rise in stock price can be attributed to a short-term recovery after previous declines, alongside a relatively better performance today compared to the sector.

Who are in the management team of Brooks Lab.?

The management team of Brooks Lab consists of Rajnish Kumar Bedi, Deepak Mahajan, and Sonia Gupta as Independent Directors, and Kaushalya Singh and Jitendra Pratap Singh as Whole Time Directors.

The management team of Brooks Lab includes the following individuals:<BR><BR>1. Rajnish Kumar Bedi - Independent Director<BR>2. Deepak Mahajan - Independent Director<BR>3. Sonia Gupta - Independent Director<BR>4. Kaushalya Singh - Whole Time Director<BR>5. Jitendra Pratap Singh - Whole Time Director<BR><BR>If you need more details about their roles or contributions, feel free to ask!

What does Brooks Lab. do?

Brooks Laboratories Ltd is a pharmaceutical manufacturing company focused on injectables, tablets, and dry syrups, with a market cap of INR 205 Cr. As of June 2026, it reported net sales of 23 Cr and a net profit of -2 Cr.

Overview:<BR>Brooks Laboratories Ltd is a pharmaceutical manufacturing company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History:<BR>Brooks Laboratories Limited was incorporated on January 23, 2002, and has been focused on manufacturing injectables, tablets, and dry syrups for domestic customers. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 23 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 205 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: 20.04% <BR>Price to Book: 1.67 <BR><BR>Contact Details:<BR>Address: Village Kishanpura, Nilagarh Road Baddi Solan Himachal Pradesh : 174101 <BR>Tel: 91-1795-654001/02/03 <BR>Email: investors@brookslabs.net <BR>Website: http://www.brookslabs.net

Who are the peers of the Brooks Lab.?

Peers of Brooks Lab. include Natural Capsules, Oxygenta Pharma, CCME Global, Syschem (India), Achyut Healthcar, Sat Kartar Life, and Accretion Pha. Brooks Lab. has a Below Average management risk and a 1-year return of -51.79%, lower than its peers, with Achyut Healthcar showing the highest return at 35.80%.

Peers: The peers of Brooks Lab. are Natural Capsules, Oxygenta Pharma, CCME Global, Syschem (India), Achyut Healthcar, Sat Kartar Life, and Accretion Pha.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sat Kartar Life, while Good management risk is found at Accretion Pha. and Syschem (India). Below Average management risk is noted at Natural Capsules, Oxygenta Pharma, Brooks Lab., CCME Global, and Achyut Healthcar. Growth is Excellent at Sat Kartar Life and Accretion Pha., Good at Syschem (India), Average at Achyut Healthcar, and Below Average at Natural Capsules, Oxygenta Pharma, Brooks Lab., and CCME Global. Capital Structure is Excellent at Sat Kartar Life, Good at Syschem (India) and Accretion Pha., and Below Average at Natural Capsules, Oxygenta Pharma, Brooks Lab., and CCME Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Achyut Healthcar at 35.80%, while the lowest is Oxygenta Pharma at -27.69%. Brooks Lab.'s 1-year return is -51.79%, which is lower than both. Additionally, Syschem (India) and CCME Global have negative six-month returns.

How big is Brooks Lab.?

As of 31st August, Brooks Laboratories Ltd has a market capitalization of 205.00 Cr, with net sales of 83.19 Cr and a net profit of 13.21 Cr reported in the latest four quarters. Shareholder's funds are 122.66 Cr, and total assets amount to 148.17 Cr as of March 2026.

As of 31st August, Brooks Laboratories Ltd has a market capitalization of 205.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Brooks Laboratories Ltd reported Net Sales of 83.19 Cr and a Net Profit of 13.21 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 122.66 Cr and Total Assets of 148.17 Cr.

Should I buy, sell or hold Brooks Laboratories Ltd?

Are Brooks Laboratories Ltd latest results good or bad?

Brooks Laboratories Ltd's latest Q4 FY26 results are concerning, showing a 21.97% increase in net sales but a drastic 72.36% decline in net profit quarter-on-quarter and a 204.11% drop year-on-year, alongside the lowest operating margin in eight quarters. This indicates significant operational challenges and vulnerabilities, suggesting investors should proceed with caution.

Brooks Laboratories Ltd's latest results for Q4 FY26 indicate a concerning performance. While the company experienced a quarter-on-quarter increase in net sales of 21.97%, this was overshadowed by a significant decline in consolidated net profit, which fell by 72.36% compared to the previous quarter and a staggering 204.11% year-on-year. <BR><BR>The operating margin also dropped to 3.36%, marking the lowest level in eight quarters, which raises serious questions about the company's ability to manage costs effectively amidst increasing competition in the pharmaceutical contract manufacturing sector. The volatility in profitability metrics suggests that the company is facing challenges in maintaining a sustainable business model, which could impact future performance.<BR><BR>Overall, the results reflect critical vulnerabilities in operational efficiency and profitability, making the latest performance more negative than positive. Investors should approach with caution given these operational challenges.

When is the next results date for Brooks Laboratories Ltd?

The next results date for Brooks Laboratories Ltd is 13 August 2026.

The next results date for Brooks Laboratories Ltd is scheduled for 13 August 2026.

How has been the historical performance of Brooks Lab.?

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

Answer:<BR>The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar'25 from 90.45 Cr in Mar'24, while total liabilities also rose to 123.69 Cr in Mar'25, reflecting a stable financial position. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25, contrasting with negative cash flows in previous years, indicating a potential turnaround in operational efficiency.

Is Brooks Lab. overvalued or undervalued?

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20 October 2025, the valuation grade for Brooks Lab. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on key financial metrics. The PE ratio stands at an exceptionally high 173.77, while the EV to EBITDA ratio is 46.27, both of which are significantly higher than its peers. In contrast, Sun Pharma has a PE ratio of 35.32 and an EV to EBITDA of 23.96, while Cipla, considered attractive, has a PE of 24.56 and an EV to EBITDA of 17.35.<BR><BR>Overall, Brooks Lab. appears to be overvalued given its high valuation ratios and poor financial performance, including a negative ROE of -10.15% and a low ROCE of 3.18%. Recent stock performance has also been disappointing, with a year-to-date decline of 35.25%, compared to a 7.97% increase in the Sensex, further reinforcing the notion that the stock is not a favorable investment at its current price of 119.75.

Who are the top shareholders of the Brooks Lab.?

The top shareholders of Brooks Lab include Atul Ranchal with 19.24%, Quant Mutual Fund at 9.9%, and individual investors collectively holding 31.86%. Foreign institutional investors hold a minimal 0.05%.

The top shareholders of Brooks Lab include the promoters, with Atul Ranchal holding the highest individual stake at 19.24%. Additionally, Quant Mutual Fund, specifically through the Quant Business Cycle Fund, is the highest public shareholder with a holding of 9.9%. The company also has mutual funds holding 9.9% through one scheme and foreign institutional investors (FIIs) holding a minimal 0.05%. Individual investors collectively own 31.86% of the company.

Has Brooks Lab. declared dividend?

No Dividend History Available